Identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions
3TR logo


Start Date
End Date
IMI2 - Call 14
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
40 273 192
EFPIA in kind
40 350 000
179 986
Total Cost
80 803 178


Many patients with autoimmune, inflammatory and allergic diseases do not respond well or at all to current treatments. A major challenge for researchers is to understand which patients are most likely to respond to which treatments. The aim of 3TR is to shed new light on the factors that determine whether or not a patient is likely to respond to a given treatment. 3TR will focus on seven diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, ulcerative colitis, Crohn’s disease, asthma, and chronic obstructive pulmonary disease (COPD). Despite their diverse symptoms, these diseases have some molecular patterns in common, suggesting that patients with different diseases may share some markers that predict the likelihood of treatment response and disease progression.

The project will analyse data and samples from 50 000 patients who took part in 50 clinical trials. They will also carry out a new clinical study that will take samples (of diseased tissue, blood, stool and other fluids) from patients before, during and after treatment. The project will add all of its data to a centralised data management platform that will make it easier to analyse using state-of-the-art methods. The samples collected and the knowledge base will be maintained beyond the end of the project to allow further research. The project will ultimately make it easier to provide the right treatment to the right patient, thereby increasing the proportion of patients taking a treatment that works for them.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Agencia Estatal Consejo Superior De Investigaciones Cientificas, Madrid, Spain
  • Azienda Ospedale Universita Padova, Padova, Italy
  • Azienda Ospedaliero-Universitaria Anna Meyer, Firenze, Italy
  • Centre Hospitalier Regional Universitaire Nancy, Nancy Cedex, France
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Christian-Albrechts-Universitaet Zu Kiel, Kiel, Germany
  • Clinique Universitaire Saint-Luc Asbl, Brussels, Belgium
  • Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain
  • Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
  • European Lung Foundation, Sheffield, United Kingdom
  • European Respiratory Society, Lausanne, Switzerland
  • Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
  • Fundacio Centre De Regulacio Genomica, Barcelona, Spain
  • Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain
  • Fundacion Publica Andaluza Progreso Y Salud M.P., Seville , Spain
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Instituto De Medicina Molecular Joao Lobo Antunes, Lisboa, Portugal
  • Karolinska Institutet, Stockholm, Sweden
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany
  • Medizinische Hochschule Hannover, Hannover, Germany
  • Orebro University, Örebro, Sweden
  • Philipps Universitaet Marburg, Marburg, Germany
  • Queen Mary University Of London, London, United Kingdom
  • Region Hovedstaden, Hilleroed, Denmark
  • Servicio Andaluz De Salud, Sevilla, Spain
  • Servicio Madrileno De Salud, Madrid, Spain
  • Stichting Vumc, Amsterdam, Netherlands
  • Technische Universitaet Dresden, Dresden, Germany
  • The Queen'S University Of Belfast, Belfast, United Kingdom
  • The University Of Manchester, Manchester, United Kingdom
  • Universita Degli Studi Del Piemonte Orientale Amedeo Avogadro, Vercelli, Italy
  • Universita Degli Studi Di Cagliari, Cagliari, Italy
  • Universita Degli Studi Di Catania, Catania, Italy
  • Universita Degli Studi Di Genova, Genova, Italy
  • Universita Di Pisa, Pisa, Italy
  • Universitat Basel, Basel, Switzerland
  • Universite De Bretagne Occidentale, Brest, France
  • Universiteit Gent, Gent, Belgium
  • Universiteit Hasselt, Hasselt, Belgium
  • Universitetet I Bergen, P.O. Box 7800, Bergen, Norway
  • University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
  • University College London, London, United Kingdom
  • University Of Glasgow, Glasgow, United Kingdom
  • University Of Leicester, Leicester, United Kingdom
  • University Of Southampton, Southampton, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
  • Universytet Medyczny W Lodzi., Lodz, Poland
  • Vib Vzw, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Alacris Theranostics GMBH, Berlin, Germany
  • Atrys Health, SA, Madrid, Spain
  • Eurice European Research And Project Office GMBH, Saarbrücken, Germany
  • Genos Doo Za Vjestacenje I Analizu, Osijek, Croatia
  • Lupus Europe, Brussels, Belgium
  • Owlstone Medical Limited, Cambridge, United Kingdom
  • Sip Service S.R.L., Milano, Italy
  • Societe De Pneumologie De Langue Francaise, Paris 6, France
Patient organisations
  • European Federation Of Asthma &Allergy Associations Ideell Forening, Brussels, Belgium
Third parties
  • Agencia Publica Empresarial Sanitaria Hospital De Poniente, El Ejido Almeria, Spain
  • Centre Hospitalier Regional Et Universitaire De Brest, Brest, France
  • Fundacion Para La Investigacion Biomedica De Cordoba, Cordoba, Spain
  • Fundacion Para La Investigacion Biomedica Del Hospital Universitario Clinico San Carlos, Madrid, Spain
  • Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental-Alejandro Otero, Granada, Spain
  • Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud, Malaga, Spain
  • Greater Glasgow Health Board, Glasgow, United Kingdom
  • Hospital Clinic De Barcelona, Barcelona, Spain
  • Orebro Lans Landsting, Orebro, Sweden
  • Region Stockholm, Stockholm, Sweden
  • Universitatsspital Basel, Basel, Switzerland
  • Universite Paris-Saclay, Saint Aubin, France
  • University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom
Project coordinator
Marta Alarcon Riquelme
Fundacion Publica Andaluza Progreso Y Salud M.P.